サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1303915

乳がんリキッドバイオプシー市場：バイオマーカー別、エンドユーザー別-2023-2030年の世界予測

Breast Cancer Liquid Biopsy Market by Biomarker, End-User - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 187 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
乳がんリキッドバイオプシー市場：バイオマーカー別、エンドユーザー別-2023-2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

乳がんリキッドバイオプシーの世界市場は大きく成長し、2023年には4億9,429万米ドル、CAGR19.42%と予測され、2030年には17億1,415万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の乳がんリキッドバイオプシー市場を評価するために不可欠です。事業戦略や製品満足度などの主要指標を検証することで、ベンダーの包括的な評価を提供し、ユーザーが特定のニーズに基づいて情報に基づいた意思決定を行えるようにします。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.乳がんリキッドバイオプシーの世界市場規模および予測は？

2.予測期間中、世界の乳がんリキッドバイオプシー市場を形成するCOVID-19の阻害要因と影響は？

3.乳がんリキッドバイオプシーの世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.乳がんリキッドバイオプシーの世界市場における競争戦略は？

5.乳がんリキッドバイオプシーの世界市場における技術動向と規制の枠組みは？

6.乳がんリキッドバイオプシーの世界市場における主要ベンダーの市場シェアは？

7.乳がんリキッドバイオプシーの世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中で乳がんの罹患率が上昇
      • 非侵襲性乳がん治療に対する需要の高まり
      • リキッドバイオプシーの研究開発のための資金の利用可能性
    • 抑制要因
      • 乳がんリキッドバイオプシーのコストが高い
    • 機会
      • 乳がんリキッドバイオプシーの早期検出における技術の進歩
      • 乳がんリキッドバイオプシー試薬の承認を増やす
    • 課題
      • 厳しい規制上の問題と不十分な償還ポリシー
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 乳がんリキッドバイオプシー市場バイオマーカー別

  • 無細胞 DNA
  • 循環腫瘍細胞
  • 細胞外小胞

第7章 乳がんリキッドバイオプシー市場：エンドユーザー別

  • 病院と医師の検査室
  • リファレンスラボ

第8章 南北アメリカの乳がんリキッドバイオプシー市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の乳がんリキッドバイオプシー市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカの乳がんリキッドバイオプシー市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ分析：主要企業別

第12章 掲載企業一覧

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. BREAST CANCER LIQUID BIOPSY MARKET RESEARCH PROCESS
  • FIGURE 2. BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2022 VS 2030
  • FIGURE 3. BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2022 VS 2030 (%)
  • FIGURE 5. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
  • FIGURE 6. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 7. BREAST CANCER LIQUID BIOPSY MARKET DYNAMICS
  • FIGURE 8. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. BREAST CANCER LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 15. BREAST CANCER LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. BREAST CANCER LIQUID BIOPSY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 5. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA , BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS , BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES , BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 9. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS & PHYSICIAN LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 12. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 14. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 15. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 16. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 17. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 19. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 21. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 23. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. AUSTRALIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 29. AUSTRALIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 31. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. INDIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 33. INDIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. INDONESIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 35. INDONESIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. JAPAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 37. JAPAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. MALAYSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 39. MALAYSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. PHILIPPINES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 41. PHILIPPINES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. SINGAPORE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 43. SINGAPORE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. SOUTH KOREA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 45. SOUTH KOREA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. TAIWAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 47. TAIWAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. THAILAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 49. THAILAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. VIETNAM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 51. VIETNAM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. DENMARK BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 56. DENMARK BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. EGYPT BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 58. EGYPT BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. FINLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 60. FINLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. FRANCE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 62. FRANCE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 64. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. ISRAEL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 66. ISRAEL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. ITALY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 68. ITALY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. NETHERLANDS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 70. NETHERLANDS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. NIGERIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 72. NIGERIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NORWAY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 74. NORWAY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. POLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 76. POLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. QATAR BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 78. QATAR BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. RUSSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 80. RUSSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 82. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SPAIN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 86. SPAIN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SWEDEN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 88. SWEDEN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SWITZERLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 90. SWITZERLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. TURKEY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 92. TURKEY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. BREAST CANCER LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 98. BREAST CANCER LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 99. BREAST CANCER LIQUID BIOPSY MARKET LICENSE & PRICING
目次
Product Code: MRR-437D4595856D

The Global Breast Cancer Liquid Biopsy Market is forecasted to grow significantly, with a projected USD 494.29 million in 2023 at a CAGR of 19.42% and expected to reach a staggering USD 1,714.15 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Breast Cancer Liquid Biopsy Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Breast Cancer Liquid Biopsy Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Biomarker, market is studied across Cell-free DNA, Circulating Tumor Cells, and Extracellular Vesicles. The Cell-free DNA is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Hospitals & Physician Laboratories and Reference Laboratories. The Reference Laboratories is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Breast Cancer Liquid Biopsy Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Breast Cancer Liquid Biopsy Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Breast Cancer Liquid Biopsy Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Breast Cancer Liquid Biopsy Market?

4. What is the competitive strategic window for opportunities in the Global Breast Cancer Liquid Biopsy Market?

5. What are the technology trends and regulatory frameworks in the Global Breast Cancer Liquid Biopsy Market?

6. What is the market share of the leading vendors in the Global Breast Cancer Liquid Biopsy Market?

7. What modes and strategic moves are considered suitable for entering the Global Breast Cancer Liquid Biopsy Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Breast Cancer Liquid Biopsy Market, by Biomarker, 2022 vs 2030
  • 4.3. Breast Cancer Liquid Biopsy Market, by End-User, 2022 vs 2030
  • 4.4. Breast Cancer Liquid Biopsy Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of breast cancer worldwide
      • 5.1.1.2. Increasing demand for non-invasive breast cancer treatment
      • 5.1.1.3. Availability of funding for liquid biopsy R&D
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of breast cancer liquid biopsy
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in early-stage detection of breast cancer liquid biopsy
      • 5.1.3.2. Increasing breast cancer liquid biopsy reagent approvals
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory issues and poor reimbursement policies
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Breast Cancer Liquid Biopsy Market, by Biomarker

  • 6.1. Introduction
  • 6.2. Cell-free DNA
  • 6.3. Circulating Tumor Cells
  • 6.4. Extracellular Vesicles

7. Breast Cancer Liquid Biopsy Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals & Physician Laboratories
  • 7.3. Reference Laboratories

8. Americas Breast Cancer Liquid Biopsy Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Breast Cancer Liquid Biopsy Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Breast Cancer Liquid Biopsy Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing